Fuling Technology
001356
KLT
831689
Hand Enterprise Solutions
300170
4
GRANDTECH
835184
5
Doushen(Beijing) Education & Technology Inc.
300010
US Stock MarketDetailed Quotes
DNTH Dianthus Therapeutics
- 22.280
- -0.380-1.68%
Close Jan 23 16:00 ET
- 22.280
- 0.0000.00%
Post 16:00 ET
659.42MMarket Cap-9.75P/E (TTM)
22.460High20.550Low172.33KVolume22.430Open22.660Pre Close3.76MTurnover1.38%Turnover RatioLossP/E (Static)29.60MShares33.77052wk High1.95P/B277.87MFloat Cap17.41452wk Low--Dividend TTM12.47MShs Float336.000Historical High--Div YieldTTM8.43%Amplitude5.136Historical Low21.803Avg Price1Lot Size
About Dianthus Therapeutics Company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Company Profile
SymbolDNTH
Company NameDianthus Therapeutics
Listing DateJun 21, 2018
Founded2015
CEOMr. Marino Garcia
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address7 Times Square,43rd Floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10036
Phone1-929-999-4055
Websitehttp://dianthustx.com
Company Executives
- Name
- Position
- Salary
- Marino Garcia
- President, Chief Executive Officer and Director
- --
- Ryan Savitz
- Chief Financial Officer, Chief Business Officer and Treasurer
- --
- Edward G. Carr
- Chief Accounting Officer
- --
- Dr. Simrat Randhawa, M.D.
- Chief Medical Officer
- --
- Adam M. Veness
- Senior Vice President, General Counsel and Secretary
- --
- Leon O. Moulder, Jr
- Chairman of the Board
- --
- Dr. Jonathan Violin, M.B.A.,PhD
- Director
- --
- Dr. Steven Joseph Romano, M.D.
- Director
- --
- Alison F. Lawton
- Independent Director
- --
- Paula Soteropoulos
- Independent Director
- --
- Anne M. McGeorge
- Independent Director
- --
- Tomas Kiselak
- Independent Director
- --
Trending Stocks
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Stocks & Industries to Watch Under Trump's Second Presidency
Key takeaways Tech stocks underwent substantial growth due to tax cuts and reduced corporate regulations in Trump's first term along with defense and aerospace
Discussing
December CPI comes in as expected, is that enough?
U.S. December CPI rose 2.9% year-on-year, aligning with expectations but marking a three-month inflation increase trend. The market reacted
In One Chart
Jan 15 22:05
Here's the Breakdown for December CPI, in One Chart